An overview of the clinical pharmacokinetics of x-ray contrast media

Clinical Pharmacokinetics

Volumn 32, Issue 3, 1997, Pages 180-193

  Bourin, Michel ^a   Jolliet, Pascale ^b   Ballereau, Françoise ^c  

^a UNIVERSITÉ DE NANTES   (France)

^b CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; DEXAMETHASONE; IODIXANOL; IOHEXOL; IONIC CONTRAST MEDIUM; IOPAMIDOL; IOPROMIDE; IOTALAMIC ACID; IOXAGLIC ACID; LIPOSOME; METRIZAMIDE; NONIONIC CONTRAST MEDIUM;

BILIARY EXCRETION; BIOTRANSFORMATION; BLOOD BRAIN BARRIER; CHEMICAL STRUCTURE; DRUG ELIMINATION; HUMAN; IMAGING; INTRAARTERIAL DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LIVER METABOLISM; NONHUMAN; PHYSICAL CHEMISTRY; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; REVIEW;

EID: 0030894855     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199732030-00002     Document Type: Review

References (85)

1. Grainger RG. Intravascular contrast media-the past, the present and the future. Br J Radiol 1982; 55: 1-18
2. Osborne ED, Sutherland CG, Scholl Jr AJ, et al. Roentgenography of the urinary tract during excretion of sodium iodide. JAMA 1923; 80: 368-73
3. Swick M. Darstellung der Niere und Harnwege in Roentgenbild durch intravenose Einbringung eines neuen kontranststoffes: des Uroselectans. Klin Wochenschr 1929; 8: 2087-9
4. Binz A. The chemistry of uroselectan. J Urol 1931; 25: 297-301
5. Hoppe JO, Larsen HA, Coulston FJ. Observations on the toxicity of a new urographic contrast medium, sodium 3,5-diacelamido-2,4,6 tri-iodobenzoate (hypaque sodium) and related compounds. J Pharmacol Exp Ther 1956; 116: 394-403
6. Wallingford VH. The development of organic iodide compounds as x-ray contrast media. J Am Pharm Assoc 1953; 42: 721-8
7. Bettmann MA, Morris TW. Recent advances in contrast agents. Radiol Clin North Am 1986; 24: 347-57
8. Almen T. Contrast agent design: some aspects on the synthesis of water-soluble contrast agents of low osmolality. J Theor Biol 1969; 24: 216-26
9. Spataro RF. Newer contrast media for urography. Radiol Clin North Am 1984; 22: 365-80
10. Holland M. Contrast agents. Diagn Imaging 1993; 23: 269-79
11. Salveson S. Acute intravenous toxicity of iohexol in the mouse and in the rat. Acta Radiol 1980; 362: 73-5
12. Shaw DD, Potts DG. Toxicology of iohexol. Invest Radiol 1985; 20 Suppl.: S10-3
13. Sovak M, Siefer HM, Ranganathan R. Combined methods for assessment of neurotoxicity: testing of new nonionic radiographic media. Invest Radiol 1980; 15: S248-53
14. Mützel W, Speck U. Tolerance and biochemical pharmacology of iopromide. Fortschr Geb Rontgenstr Nuklearmed 1983; Suppl. 118: 11-7
15. Bäck SE, Krutzen E, Nilsson-Ehle P. Contrast media and glomerular filtration: dose dependance of clearance for three agents. J Pharm Sci 1988; 77: 765-7
16. Eloy R, Corot C, Belleville J. Contrast media for angiography: physicochemical properties, pharmacokinetics and biocompatibility. Clin Mater 1991; 7: 89-197
17. Krause W. Preclinical characterization of iopromide. Invest Radiol 1994; 29: S21-31
18. Deutsch AL, Gerber KH, Haigler FH, et al. Effects of low osmolality contrast materials on coronary hemodynamics, myocardial function, and coronary sinus osmolality in normal and ischemic states. Invest Radiol 1982; 17: 284-91
19. Morris TW, Kern MA, Katzberg RW. The effects of media viscosity on hemodynamics in selective arteriography. Invest Radiol 1982; 17: 70-6
20. Dawson P. The clotting issue: etiologic factors in thromboembolism. I: chemistry, pharmacology and toxicity of angiographic contrast agents. Invest Radiol 1993; 28 : S25-30
21. Ansell G, Tweedie MCK, West CR, et al. The current status of reactions to intravenous contrast media. Invest Radiol 1980; 15: S32-9
22. Shehadi WH, Toniolo G. Adverse reactions to contrast media. Radiol 1980; 137: 299-302
23. McClennam BL. Low-osmolality contrast media: premises and promises. Radiology 1987; 162: 1-8
24. Sage MR. Kinetics of water soluble contrast media in the central nervous system. Am J Radiol 1983; 141: 815-24
25. Haavaldsen J. Iohexol: introduction. Acta Radiol 1980; Suppl. 362: 9-11
26. Widrich WC, Robbins AH, Rommel AJ, et al. Iopamidol: a nonoionic contrast agent for peripheral arteriography. Radiology 1982; 145: 53-5
27. Wolf GL, Mulry CS, Kilzer K, et al. New angiographic agents with less fibrillatory propensity. Invest Radiol 1981; 16: 320-3
28. Salveson S. Acute toxicity of metrizamide. Acta Radiol 1973; 335: 5-13
29. Katayama H, Yamaguchi K, Kozuka T, et al. Adverse reactions to ionic and nonionic contrast media. Radiology 1990; 175: 621-8
30. Farmer CD, Tauxe WN, Maher FT, et al. Measurement of renal function with radioiodinated diatrizoate and o-iodohippurate. J Clin Pathol 1967; 47: 9-16
31. Krutzen E, Bäck SE, Nilson-Ehle I, et al. Plasma clearance of a new contrast agent, iohexol: a method for the assessment of glomerular filtration rate. J Lab Clin Med 1984; 104: 955-61
32. Bäck SE. Contrast media as markers for glomerular filtration [thesis]. Lund: Lund University, 1988
33. Olsson B, Aulie ASE, Sven K, et al. Human pharmacokinetics of iohexol a new nonionic contrast medium. Invest Radiol 1983; 18: 177-82
34. Dean PB, Kivisaari L, Kormano M. Contrast enhancement pharmacokinetics of six ionic and nonionic contrast media. Invest Radiol 1983; 18: 368-74
35. Kormano M, Spataro RF, Soimakallio S, et al. Comparison of contrast enhancement pharmacokinetics of contrast media in clinical patients. In: Amiel M, Mreau JF. Contrast media in radiology. Berlin: Springer Verlag, 1982: 115-9
36. Gardeur D, Lautrou J, Millard JC, et al. Pharmacokinetics of contrast media: experimental results in dog and man with CT implications. J Comput Assist Tomogr 1980; 4 (2): 178-85
37. Hervé F, Urien S, Albengres E, et al. Drug binding in plasma, a summary of recent trends in the study of drug and hormone binding. Clin Pharmacokinet 1994; 26: 44-58
38. Carstensen F, Wurbs D. Contrast medium resorption in ERCP. Z Gastroenterol 1993; 31: 369-75
39. Marti-Bonmati L, Ronchera-Oms CL, Espinos MA, et al. Assessing the effectiveness of X-ray contrast media for abdominal computed tomographic examinations: comparison of four low-osmolality agents. J Clin Pharm Ther 1995; 20: 75-81
40. Cittadini G, Garlaschi G, Russo S, et al. Some operational aspects about the pharmacokinetics of uroangiographic iodinated contrast media. Radiol Med Torino 1986; 72: 25-8
41. Duchin KL, Drayer BP, Ross M, et al. Pharmaocokinetics of iopamidol after intrathecal administration in humans. Am J Neuroradiol 1986; 7: 895-8
42. Tirone P, Ferrari D. Pharmacokinetics of iopamidol. Rays 1982; 7: 73-82
43. Klingmueller V, Brockmeier D, Immel V, et al. The pharmacokinetic of iopamidol and ioxitalamate: a comparison of low and high osmolality contrast media. Ann Radiol 1984; 27: 263
44. Lorusso V, Luzzani F, Bertani F, et al. Pharmacokinetics and tissue distribution of iomeprol in animals. Eur J Radiol 1994; 18: S13-20
45. Hartwig P, Mutzel W, Taenzer V. Pharmacokinetics of iohexol, iopamidol, iopromide, and iosimide compared with meglumine diatrizoate. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1989; Suppl. 128: 220-3
46. Krause W, Schuhmann-Giamieri G, Staks T, et al. Dose proportionality of iopromide pharmacokinetics and tolerability after IV injection in healthy volunteers. Eur J Clin Pharmacol 1994; 46: 339-43
47. Stake G, Monclair T. A single plasma sample method for estimation of the glomerular related formula for the distribution volume of iohexol. Scand J Clin Lab Invest 1991; 51: 335-42
48. Svaland MG, Haider T, Langseth-Manrique K, et al. Human pharmacokinetics of iodixanol. Invest Radiol 1992; 27: 130-3
49. Rosati G. Clinical pharmacology of iomeprol. Eur J Radiol 1994; 18 Suppl.: S51-60
50. Dean PB, Kivisaari L, Kormano M. The diagnostic potential of contrast enhancement pharmacokinetics. Invest Radiol 1978; 13: 533-40
51. Newhouse JH. Fluid compartment distribution of intravenous iothalamate in the dog. Invest Radiol 1977; 12: 364-7
52. Guidolet J, Barbe R, Borsson F, et al. Subcellular localization of uroangio-graphic contrast by I-125 labelled media. Invest Radiol 1980; 15: 215-9
53. Täuber U, Mützel W, Schulze PE. Whole body autoradiographic distribution studies on nonionic X-Ray contrast agents in pregnants rats. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1989; Suppl. 128: 215-9
54. Bourrinet P, Dencausse A, Havard P, et al. Transplacental passage and milk excretion of iobitridol. Invest Radiol 1995; 30: 156-8
55. Morris TW, Fischer HW. The pharmacology of intravascular radiocontrast media. Ann Rev Pharmacol Toxicol 1986; 26: 143-60
56. Burgener FA, Hamlin DJ. Contrast enhancement in abdominal CT: bolus vs. infusion. Am J Roentgenol 1981; 137: 351-8
57. Partanen K, Kormano M, Kivimäki T, et al. Comparison of iohexol and metrizamide in dynamic C T of the upper abdomen. Eur J Radiol 1984; 4: 227-8
58. Owman T, Olin T. Biliary excretion of urographic contrast media (iothalamate, diatrizoate, P286 and metrizamide). Ann Radiol 1978; 21: 309-12
59. Bourin M, Laporte V, Guenzet J, et al. Pharmacokinetic study of ioxaglate, a low osmolality contrast medium, in patients with renal failure. Int J Clin Pharmacol Ther Toxicol 1986; 24: 614-21
60. Dean PB. Pharmacokinetics of contrast media in body CT. In: Fuchs WA, editor. Contrast enhancement in body computerized tomography. Amsterdam: Excerpta Medica International Congress Series, 1980: 20-7
61. McKinstry DN, Rommel AJ, Sugerman A. Pharmacokinetics, metabolism and excretion of iopamidol in healthy subjects. Invest Radiol 1984; 19: 171-4
62. Cattrell WR. Excretory pathways for contrast media. Invest Radiol 1970; 5: 473-8
63. Morin JP, Boutelet I, Toutain H, et al. Pharmacocinétique et accumulation rénale comparatives de trois produits de contraste iodés: l'acide ioxitalamique, l'acide ioxaglique et l'iohexol chez le lapin. Pathol Biol 1987; 35: 1215-20
64. Mützel W, Speck U, Weinnann HJ. Pharmacokinetics of iopromide in rat and dog. Fortschr Geb Rontgenstr Nuklearmed 1983; Suppl. 118: 85-90
65. Lundquist S, Leander P. The extrarenal clearance of water-soluble iodinated contrast media: an experimental study in rabbits. Invest Radiol 1991; 26: S75-9
66. Speck U, Schmidt R, Volkhardt V, et al. The effect of position on the passage of metrizamide (amipaque), meglumine iocarmate (dimer X) and ioserinate (myelogralin) into the blood after lumbar myelography. Neuroradiology 1978; 14: 251-6
67. Speck U, Mutzel W, Mannesmann G, et al. Pharmacology of nonionic dimers. Invest Radiol 1980; 6: 317-21
68. Pitre D, Zingales MF, Trevisan C. Urinary excretion of iopamidol following intrathecal administration. Neuroradiology 1983; 25: 37-8
69. Berg KJ, Kolmannskog F, Lillevold PE, et al. Iopentol in patients with chronic renal failure: its effects on renal function and its use as glomerular filtration rate parameter. Scand J Clin Lab Invest 1992; 52: 27-33
70. Thomsen HS, Vestgaard A, Nielsen SL, et al. Renal clearance of an ionic high-osmolar and a nonionic low-osmolar contrast medium. Invest Radiol 1991; 26: 564-8
71. Zurth C. Mechanism of renal excretion of various X-ray contrast materials in rabbits. Invest Radiol 1984; 19: 110-6
72. Difazio LT, Singhvi SM, Heald AF, et al. Pharmacokinetic of iodamine in normal subjects, and in patients with renal impairment. J Clin Pharmacol 1978; 18: 35-40
73. Sjoberg S, Almen T, Golman K. Excretion of urographic contrast media-I-Iohexol and other media during free urine flow in the rabbit. Acta Radiol 1980; Suppl. 362: 93-8
74. Benness GT. Urographic contrast agents: a comparison of sodium and methylglucamine salts. Clin Radiol 1970; 21: 150-6
75. Golman K, Wilk I. Renal excretion mechanism of a nonionic contrast agent. Invest Radiol 1979; 14: 224-7
76. Nagel R, Leistenschneiden W, Speck U, et al. Pharmacokinetics and cliniical studies of ioglicinate, a new constrast medium for intravenous urography. Int J Clin Pharmacol 1978; 16: 49-53
77. Dawson P, Peters AM. Short communication: renal function and the excretion of contrast agents. Br J Radiol 1996; 69: 567-9
78. Donnelly PK, Burwell N, McBurney A, et al. Clearance of iopamidol, a non-ionic contrast medium, by CAPD in patients with end-stage renal failure. Br J Radiol 1992; 65: 1108-13
79. Svaland MG, Kolmannskog F, Lillevold PE, et al. Pharmaco kinetics of iopentol in patients with chronic renal failure. Acta Radiol 1992; 33: 482-4
80. Evans JR, Cutler RE, Forland SC. Pharmacokinetics of iothalamate in endstage renal disease. J Clin Pharmacol 1988; 28: 826-30
81. Von Klingmueller V, Brockmeier D, Schuster W, et al. Pharmakokinetische Aspekle der Ausscheidurgsurographie im Kindesalter. Fortschr Geb Rontgenstr Nuklearmed 1983; 138: 316-22
82. Yeung WT, Lee TY, Del Maestro RF, et al. Effects of steroid on iopamidol blood-brain transfer constant and plasma volume in brain tumors measured with X-ray computed tomography. J Neurooncol 1993; 18: 53-60
83. Wowra B, Cremer K, Stricker H, et al. Intraneoplastic application of metrizamide-containing liposomes: kinetic studies with computed tomography. J Neurooncol 1992; 14: 9-18
84. Krause W, Leike J, Sachse A, et al. Characterization of iopromide liposomes. Invest Radiol 1993; 28: 1028-32
85. Doucet D, Meyer D, Chambon C, et al. Blood-pool x-ray contrast agents: evaluation of a new iodinated polymer. Invest Radiol 1991; 26: S53-4